Pollini J, Soutif C, Barnouin F, Briat C, Meulders Q, Teissier M
Service de médecine interne-néphrologie-hémodialyse, Hôpital Henri Duffaut, Avignon.
Nephrologie. 1998;19(5):245-53.
To assess the cost of end stage renal failure treatment was the target of studies we achieved during the last ten years. We showed how much the global cost was favourably influenced by the number of available therapeutic methods. In a recent study, reported here, we followed a new methodology more often used today in our public hospitals. The comparison of analytical accountancy data with computerized medical informations as given by identification of Diagnosis Related Groups probably allows better assessment of "real cost". But is this approach really useful for nephrologists? These frequently asked questions cannot be performed without the participation of physicians. The question remains whether or not these studies will contribute to improve the quality of care and to allow some saving. We also hope sharing with readers of "Nephrologie" these kinds of considerations as well as our opinions and doubts.
评估终末期肾衰竭治疗成本是我们在过去十年所开展研究的目标。我们展示了可用治疗方法的数量如何对全球成本产生有利影响。在本文所报告的一项近期研究中，我们采用了一种如今在我们公立医院中更常使用的新方法。将分析会计数据与通过诊断相关分组识别得出的计算机化医疗信息进行比较，或许能更好地评估“实际成本”。但这种方法对肾病科医生真的有用吗？如果没有医生的参与，这些常见问题就无法得到解答。这些研究是否会有助于提高医疗质量并实现一些节约，这一问题仍然存在。我们也希望与《肾病学》的读者分享这类思考以及我们的观点和疑问。
